ECSP099778A - Dosis intravenosa y oral de un inhibidor p2y12 de acción directa y reversible - Google Patents

Dosis intravenosa y oral de un inhibidor p2y12 de acción directa y reversible

Info

Publication number
ECSP099778A
ECSP099778A EC2009009778A ECSP099778A ECSP099778A EC SP099778 A ECSP099778 A EC SP099778A EC 2009009778 A EC2009009778 A EC 2009009778A EC SP099778 A ECSP099778 A EC SP099778A EC SP099778 A ECSP099778 A EC SP099778A
Authority
EC
Ecuador
Prior art keywords
intravenous
inhibitor
direct
oral dose
reversible action
Prior art date
Application number
EC2009009778A
Other languages
English (en)
Spanish (es)
Inventor
Anjali Pandey
Pamela B Conley
Patrick Andre
Daniel D Gretler
Athiwat Hutchaleelaha
David R Phillips
Carroll Anna Crew Scarborough
Huang Wolin
Original Assignee
Portola Pharm Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Portola Pharm Inc filed Critical Portola Pharm Inc
Publication of ECSP099778A publication Critical patent/ECSP099778A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/216—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acids having aromatic rings, e.g. benactizyne, clofibrate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Emergency Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Plural Heterocyclic Compounds (AREA)
EC2009009778A 2007-05-02 2009-12-02 Dosis intravenosa y oral de un inhibidor p2y12 de acción directa y reversible ECSP099778A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US91564907P 2007-05-02 2007-05-02
US94792107P 2007-07-03 2007-07-03

Publications (1)

Publication Number Publication Date
ECSP099778A true ECSP099778A (es) 2010-01-29

Family

ID=39587015

Family Applications (1)

Application Number Title Priority Date Filing Date
EC2009009778A ECSP099778A (es) 2007-05-02 2009-12-02 Dosis intravenosa y oral de un inhibidor p2y12 de acción directa y reversible

Country Status (17)

Country Link
US (2) US20090048216A1 (enExample)
EP (1) EP2079464A2 (enExample)
JP (1) JP2010526101A (enExample)
KR (1) KR20100029746A (enExample)
CN (1) CN101795682A (enExample)
AU (1) AU2008247483A1 (enExample)
BR (1) BRPI0811476A2 (enExample)
CA (1) CA2686203A1 (enExample)
CO (1) CO6241104A2 (enExample)
EA (1) EA200901473A1 (enExample)
EC (1) ECSP099778A (enExample)
GT (1) GT200900284A (enExample)
IL (1) IL201834A0 (enExample)
MA (1) MA31663B1 (enExample)
MX (1) MX2009011843A (enExample)
TN (1) TN2009000451A1 (enExample)
WO (1) WO2008137753A2 (enExample)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ZA200804241B (en) * 2005-11-03 2009-09-30 Portola Pharm Inc [4-(6-halo-7-substituted-2,4-dioxo-1,4-dihydro-2H-quina-zolin-3-yl)-phenyl]-5-chlorothiophen-2-yl-sulfonylureas and forms and methods related thereto
CA2678492A1 (en) * 2007-03-06 2008-09-12 Novartis Ag Bicyclic organic compounds suitable for the treatment of inflammatory or allergic conditions
US20090156620A1 (en) * 2007-05-02 2009-06-18 Portola Pharmaceuticals, Inc. [4-(6-fluoro-7-methylamino-2,4-dioxo-1,4-dihydro-2h-quinazolin-3-yl)-phenyl]-5-chloro-thiophen-2-yl-sulfonylurea salts, forms and methods related thereto
MX2009011836A (es) * 2007-05-02 2010-05-20 Portola Pharm Inc Sales de [4-(6-fluoro-7-metilamino-2,4-dioxo-1,4-dihidro-2h-quinaz olin-3-il)-fenil]-5-cloro-tiofen-2-il-sulfonilurea, en diferentes formas cristalinas, y composiciones farmaceuticas de las mismas.
US9427448B2 (en) * 2009-11-11 2016-08-30 The Medicines Company Methods of treating, reducing the incidence of, and/or preventing ischemic events
EP2384196B1 (en) * 2008-12-30 2017-09-13 Johansson, Pär Methods of identifying critically ill patients at increased risk of development of organ failure and compounds for the treatment hereof
US10376532B2 (en) 2009-11-11 2019-08-13 Chiesi Farmaceutici, S.P.A. Methods of treating, reducing the incidence of, and/or preventing ischemic events
PT2498731T (pt) 2009-11-11 2020-02-21 Chiesi Farm Spa Métodos de tratamento ou prevenção de uma trombose de endoprótese
CA2785487C (en) * 2009-12-23 2017-11-28 Ratiopharm Gmbh Solid pharmaceutical dosage form of ticagrelor
EP2523657A1 (en) 2010-01-12 2012-11-21 Portola Pharmaceuticals, Inc. Pharmaceutical composition and dosage forms of elinogrel and methods of use thereof
WO2011137459A1 (en) * 2010-04-30 2011-11-03 Portola Pharmaceuticals, Inc. Dosage forms of elinogrel and methods of injectable administration thereof
EP2646827A1 (en) * 2010-12-01 2013-10-09 INSERM (Institut National de la Santé et de la Recherche Médicale) Method and kits for determining platelet susceptibility to activation in a patient
EP2646434B1 (en) * 2010-12-03 2019-05-15 Portola Pharmaceuticals, Inc. Pharmaceutical compositions, dosage forms and new forms of the compound of formula (i), and methods of use thereof
JP7580918B2 (ja) 2017-03-15 2024-11-12 イドルシア・ファーマシューティカルズ・リミテッド Ｐ２ｙ１２受容体アンタゴニストの皮下投与
EP3641784A1 (en) 2017-06-23 2020-04-29 Chiesi Farmaceutici S.p.A. Method of preventing of systemic-to-pulmonary-artery shunt thrombosis
CN107462648B (zh) * 2017-08-21 2019-09-27 盐城锦明药业有限公司 一种Cangrelor中间体腺苷-2-硫酮的高效液相色谱检测方法

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6906063B2 (en) 2000-02-04 2005-06-14 Portola Pharmaceuticals, Inc. Platelet ADP receptor inhibitors
ZA200804241B (en) 2005-11-03 2009-09-30 Portola Pharm Inc [4-(6-halo-7-substituted-2,4-dioxo-1,4-dihydro-2H-quina-zolin-3-yl)-phenyl]-5-chlorothiophen-2-yl-sulfonylureas and forms and methods related thereto

Also Published As

Publication number Publication date
TN2009000451A1 (en) 2011-03-31
MA31663B1 (fr) 2010-09-01
WO2008137753A2 (en) 2008-11-13
EA200901473A1 (ru) 2010-06-30
BRPI0811476A2 (pt) 2014-11-04
CA2686203A1 (en) 2008-11-13
CN101795682A (zh) 2010-08-04
CO6241104A2 (es) 2011-01-20
US20120009172A1 (en) 2012-01-12
KR20100029746A (ko) 2010-03-17
JP2010526101A (ja) 2010-07-29
IL201834A0 (en) 2010-06-16
GT200900284A (es) 2012-01-31
EP2079464A2 (en) 2009-07-22
MX2009011843A (es) 2010-04-22
WO2008137753A3 (en) 2009-02-12
US20090048216A1 (en) 2009-02-19
AU2008247483A1 (en) 2008-11-13

Similar Documents

Publication Publication Date Title
ECSP099778A (es) Dosis intravenosa y oral de un inhibidor p2y12 de acción directa y reversible
CL2013001136A1 (es) Un agente inhibitorio de la fosfodiesterasa 7 (pde7) para ser usado en el tratamiento o la reduccion de la posibilidad de una adiccion; y composicion farmaceutica, forma de dosificacion unitaria y kit farmaceutico que incluyen al inhibidor de fosfodiesterasa 7 (pde7) y un agente terapeutico adicional.
ECSP099376A (es) Inhibidores de la actividad de la akt
UY31205A1 (es) Composiciones de tabletas de desintegracion oral de lamotrigina
PL1986669T3 (pl) Zastosowanie Bifidobacterium longum do zapobiegania i leczenia zapalenia
BR112015020466A8 (pt) inibidores de cdc7, seus usos, e composição farmacêutica
MX2020010412A (es) Inhibidores de tirosina quinasa de bruton.
SV2009003335A (es) Formulaciones para el cancer
GT200900008A (es) Derivados novedosos de aminopiridina que tienen acción inhibidora selectiva sobre aurora a
CL2011000798A1 (es) Uso de etexilato de dabigatran o una sal del mismo para preparar un medicamento util para la prevencion del ictus en pacientes que padecen fibrilacion auricular.
GT200900283A (es) "terapia de combinación con un compuesto actuando como un inhibidor del receptor adp plaquetario".
CL2014000297A1 (es) Uso de un inhibidores de corrientes "funny" (if) o una de sus sales para utilizar en un metodo de tratamiento y prevencion de la insuficiencia cardiaca en felinos .
NO20082120L (no) Behandling og forebyggelse av mikroangiopati
CL2011000806A1 (es) Uso de etexilato de dabigatran o una sal del mismo para preparar un medicamento util para la prevencion del ictus en pacientes que padecen fibrilacion auricular.
MX2009004017A (es) Usos de los compuestos carboxi-amido triazol y sus sales.
AR096892A1 (es) Una combinación farmacéutica para el tratamiento del melanoma
UY35859A (es) ?combinación farmacéutica que comprende amlodipina, losartán y rosuvastatina?.
HN2003000063A (es) Derivados de nicotinamida y una sal de tiotropio en combinacion para el tratamiento de enfermedades.
CL2008003699A1 (es) Nanopartícula que comprende pioglitazona y un polímero biocompatible, preparación farmacéutica que la contiene; stent (endoprótesis vascular) que la porta; y su uso en la profilaxis o tratamiento de enfermedades arterioescleróticas.
BRPI0916540B8 (pt) inibidores do canal de ânion de superficíe de plasmódio como agentes antimaláricos
CL2009001841A1 (es) Uso de una composición de liberación sostenida de 4-aminopiridina para preparar un medicamento útil para tratar esclerosis multiple en un sujeto.
MX2019003039A (es) Forma de dosificacion de alivio prolongado.
CY1116672T1 (el) Χρηση αδαπαλενης και βενζοϋλυπεροξειδιου για την μακροχρονια αντιμετωπιση της κοινης ακμης
AR054595A1 (es) Formulaciones/composiciones farmaceuticas de guanfacina apropiadas para forma de administracion diaria en una unica dosis
CL2007002878A1 (es) Agente farmaceutico que comprende 1) un inhibidor de her2 que tiene un esqueleto de pirrolopirimidina o de pirazolopirimidina y 2) un agente terapeutico hormonal o anticancerigeno en combinacion; y uso pra la prevencion o el tratamiento del cancer.